Get started
Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

TNXP trade ideas

TNXP – Tonix Pharmaceuticals – 30-Min Long Trade Setup !📈 🚀 🔹 Asset: TNXP (NASDAQ) 🔹 Timeframe: 30-Min Chart 🔹 Setup Type: Symmetrical Triangle Breakout + Trendline Support 📊 Trade Plan (Long Position) ✅ Entry Zone: Above $26.53 (Breakout zone + trendline support) ✅ Stop-Loss (SL): Below $23.81 (Previous support & trendline base) 🎯 Take Profit Targets 📌 TP1: $31.64 (Previous resistance zone) 📌 TP2: $37.76 (Major resistance / measured move target) 📊 Risk-Reward Ratio Calculation 📉 Risk (SL Distance): $26.53 - $23.81 = $2.72 risk per share 📈 Reward to TP1: $31.64 - $26.53 = $5.11 → (1.88:1 R/R) 📈 Reward to TP2: $37.76 - $26.53 = $11.23 → (4.13:1 R/R) 🔍 Technical Analysis & Strategy 📌 Triangle Breakout: Price consolidating and now testing triangle resistance 📌 Volume Pick-up Expected: Ideal breakout candidate if volume expands above $26.53 📌 Trendline Support Holding: Consistent higher lows with bullish structure 📌 Break + Retest Zone: Yellow zone acting as breakout confirmation ⚙️ Trade Execution & Risk Management 📊 Wait for a 30-min bullish close above $26.53 📉 Trailing Stop Strategy: Move SL to breakeven after hitting TP1 💰 Partial Profit Booking Strategy ✔ Book 50% at TP1 = $31.64 ✔ Let the rest ride toward TP2 = $37.76 ✔ Trail SL above entry to secure gains ⚠️ Breakout Failure Risk ❌ Setup invalid if price breaks below $23.81 ❌ Avoid entry without clear breakout close above $26.53 🚀 Final Thoughts ✔ Triangle breakout + trendline support = solid bullish setup ✔ Reward potential up to 4.13:1 R/R ✔ Clean structure, strong confluence, manageable risk 🔗 #TNXP #NASDAQ #BreakoutTrade #SwingTrading #ProfittoPath #TechnicalSetup #TriangleBreakout #TrendlineSupport #StockTrading #RiskReward #PharmaStocks
NASDAQ:TNXPLong
by ProfittoPath
TNXP: Tonix Pharmaceuticals, TIME FOR PROFITS?!? ;)What's up my financial amigos and amigas! Hope all is well. Haven't posted in awhile but thought I'd share this: TNXP. Pharmaceutical company with decent history and negative earnings but continued improvement and growth. Working on approval from FDA after successful phase 3 trial of Fibromyalgia drug (among other projects). Obviously, this is a more risky stock/company (and of course, I do enjoy a good gamble). This could certainly plummet more and/or result in being stuck in longer term position than desired. However, based on prior patterns of "mooning," coupled with my charting projections and current positive "news," I think it's time for at least a 100% pump. We'll see...not financial advise and do your own research (and send me 10% of profits...jk, sort of). Projection: >10 trading days for 50-100+ percent Good luck trading
NASDAQ:TNXP
by TheLuckyNoob
TNXP (Request counter) Requested Analysis Resistance at 3.02 and 4.75. Generally, I would not recommend this kind of chart and industry. The biotech industry tends to have a very volatile nature. It is usually driven by news/rumors. Extremely hard to predict. If you're lucky, you may get a 20-30% rally price due to some random news. OR.. you can be stuck at this counter for a very very very long time. I would take this as a gambling trade that is not dependent on fundamentals or technicals. Just a pure gamble for some news to come along. If you must trade this, play small. I personally would avoid it.
NASDAQ:TNXP
by NimbusCapital
TNXP Tonix Pharmaceuticals produces the Monkeypox Vaccine ! Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox. But that`s not all! They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil. Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high impact product candidates,” “By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.” TNX-2900 received Orphan-Drug designation by the FDA for the treatment of PWS in March 2022. On this strong pipeline, on 4/18/2022 Noble Financial Initiated Coverage on TNXP with an Outperform rating and a price target of $19.20, while Alliance Global Partners has a price target of $64. I expect TNXP Tonix Pharmaceuticals to be at least $10 per share. Looking forward to read your opinion about it.
NASDAQ:TNXPLong
by TopgOptions
2